Search
Filters
Clear All
  • 1
  • 7

Phase

  • 3
  • 1
  • 3
  • 8
  • 1

Found 8 nabil-adra-md trials

A listing of nabil-adra-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer with selective bladder sparing

J
Jennifer King
18 years or above
All genders
Phase 2
Interventional
What is the purpose of this study?Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completingwo cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CThe …
Learn More

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

N
Nabil Adra, MD
18 years or above
All genders
Phase 2
Interventional
What is the purpose of this study?This is an open label randomized phase II trial of maintenance oral etoposide vs. observationwith relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood(PBSCT).THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened …
Learn More

Collection of Specimens and Clinical Data to Create a Biorepository for the Genitourinary Oncology Program

N
Nabil Adra, MD
18 years - 100 years
All genders
The purpose of this study is to collect a variety of blood and cancer tissue specimens from patients with advanced kidney, bladder or prostate cancer.
Learn More

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

N
Nabil Adra, MD
18 years - 100 years
Male
Phase 3
What is the purpose of this study?The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.The intention of the study is to demonstrate superiority of Saruparib …
Learn More

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

N
Nabil Adra, MD
All genders
Phase 2
Interventional
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib forwith incurable, refractory germ cell tumors. Patients will be treated until evidencedisease progression, non-compliance with study protocol, unacceptable major toxicity, atubject's own request for withdrawal, or if the study closes for any reason.
Learn More

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

N
Nabil Adra, MD
18 years - 100 years
All genders
The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 Inhibitor for individuals with urothelial carcinoma (cancer of the urinary tract).
Learn More

PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER

N
Nabil Adra, MD
18 years - 100 years
All genders
The purpose of this study is to compare the effects, good and/or bad, of adding either prostate removal surgery or radiation therapy to standard systemic therapy (SST), which is used to treat prostate cancer.
Learn More

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

N
Nabil Adra, MD
18 years - 100 years
All genders
This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.
Learn More